Vertex Pharmaceuticals, Inc. Second Quarter Earnings Sneak Peek
Vertex Pharmaceuticals, Inc. (NASDAQ:VRTX) will unveil its latest earnings on Thursday, July 28, 2011. Vertex Pharmaceuticals is engaged in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases.
Vertex Pharmaceuticals, Inc. Earnings Preview Cheat Sheet
Wall St. Earnings Expectations: The average estimate of analysts is for net loss of 92 cents per share, a wider loss from the year earlier quarter net loss of 83 cents. During the past three months, the average estimate has moved down from a loss of 87 cents. Between one and three months ago, the average estimate moved down, but has risen from a loss of 93 cents during the last month.
Past Earnings Performance: The company fell in line with estimates last quarter after topping forecasts the quarter before. After coming in above the mean estimate by one cent in the fourth quarter of the last fiscal year, the company fell in line with expecations by reporting a loss of $1.05 per share last quarter.
Wall St. Revenue Expectations: On average, analysts predict $52.6 million in revenue this quarter, a rise of 66.5% from the year ago quarter. Analysts are forecasting total revenue of $729.7 million for the year, a rise of more than fivefold from last year’s revenue of $143.4 million.
Analyst Ratings: Analysts seem relatively indifferent about Vertex Pharmaceuticals with 12 of 23 analysts surveyed maintaining a hold rating.
The company’s revenue has now risen for two straight quarters. In first quarter, revenue increased more than threefold to $73.7 million from the year earlier quarter. In the fourth quarter of the last fiscal year, the figure rose 93.3%.
Competitors to Watch: Merck & Co., Inc. (NYSE:MRK), Johnson & Johnson (NYSE:JNJ), GlaxoSmithKline plc (NYSE:GSK), InterMune, Inc. (NASDAQ:ITMN), Gilead Sciences, Inc. (NASDAQ:GILD), Pharmasset, Inc. (NASDAQ:VRUS), Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX), Bristol Myers Squibb Co. (NYSE:BMY), Abbott Laboratories (NYSE:ABT), and Human Genome Sciences (NASDAQ:HGSI).
Stock Price Performance: During May 25, 2011 to July 22, 2011, the stock price had fallen $4.59 (-8.3%) from $55.57 to $50.98. The stock price saw one of its best stretches over the last year between June 17, 2011 and June 29, 2011 when shares rose for nine-straight days, rising 16.1% (+$7.26) over that span. It saw one of its worst periods between March 29, 2011 and April 6, 2011 when shares fell for seven-straight days, falling 5.1% (-$2.48) over that span. Shares are up $15.95 (+45.5%) year to date.
(Source: Xignite Financials)